Excalibur’s rapid antigen test gets regulatory approval for mass screening

Excalibur Healthcare Services Ltd has announced that its rapid antigen test has received regulatory approval to be used in mass screening for Covid-19 in asymptomatic, pre-symptomatic, and symptomatic populations.

With the latest approval from the Medicines & Healthcare Products Regulatory Agency (MHRA), the Excalibur Rapid SARS COV-2 Antigen Screening test can be deployed to rapidly track down infectious individuals capable of spreading the disease.

To date, Covid-19 tests in the UK have been approved for use only on people who exhibit symptoms.

Professor Sir Chris Evans, chairman of Excalibur Healthcare Services, said: “This test can be used with complete confidence in a wide range of everyday settings and will help organisations and businesses operate with the knowledge that their personnel are not infectious at the time of testing.

“It is fast, accurate, dependable and affordable and will screen out any highly infectious people quickly and reliably. Our test can now play a key role in helping us all combat the spread of coronavirus.”

The Excalibur test has successfully been used in screening trials in hospitals, healthcare environments, offices, retail chains, workplaces, care homes, and others.